Antibe - A low risk buyAntibe is either doing 'B' or has probably bottomed out.
Trend lines and crossovers also support an up move.
Very likely to hit the 1st target. Could hit the second and continue the up move if the +ve divergence stays.
Next report date
Report period
Q4 2023
EPS estimate
−0.07USD
Revenue estimate
—
−0.2623USD
−14.14 MUSD
47.44 M
About Antibe Therapeutics, Inc.
Sector
CEO
Daniel Legault
Headquarters
Toronto
Website
Employees (FY)
11
Founded
2009
FIGI
BBG006YTKW75
Antibe Therapeutics, Inc. is a biotechnology company, which engages in the development of medicines for pain and inflammation. It operates through the Antibe Therapeutics and Citagenix segments. The Antibe Therapeutics segment focuses on the development of pharmaceutical products. The Citagenix segment is involved in the development and sale of regenerative medicines serving the dental and orthopedic marketplaces. The company was founded by Andre Buret, John Wallace, and Giuseppe Cirino on May 5, 2009 and is headquartered in Toronto, Canada.
inverse head and shouldersOn the daily we have the rsi above the 50 level pointing up up and a macd kiss on the positive side. Looking at the price action we can see the price action above the 8, 21, and 55 ema , but will under the 200 ema, as well as a neckline for a possible inverse head and shoulders breakout. They have
$ATBPF Antibe Therapeutics Inc, bull run to continue?Trade opportunity to the top of a well defined channel, with a possible 13% gain.
Indicators quite bullish as MACD reverses of the zero line, histogram ticking higher and green.
RSI in strong move.
Company profile
Antibe Therapeutics, Inc. is a biotechnology company, which engages in the developmen
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ATBPF is 0.2156 USD — it has increased by 13.47% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Antibe Therapeutics, Inc. stocks are traded under the ticker ATBPF.
Antibe Therapeutics, Inc. is going to release the next earnings report on Jun 27, 2024. Keep track of upcoming events with our Earnings Calendar.
ATBPF stock is 29.80% volatile and has beta coefficient of −0.14. Check out the list of the most volatile stocks — is Antibe Therapeutics, Inc. there?
ATBPF earnings for the last quarter are −0.07 USD per share, whereas the estimation was −0.09 USD resulting in a 16.67% surprise. The estimated earnings for the next quarter are −0.09 USD per share. See more details about Antibe Therapeutics, Inc. earnings.
Antibe Therapeutics, Inc. revenue for the last quarter amounts to 2.18 M USD despite the estimated figure of 1.92 M USD. In the next quarter revenue is expected to reach 2.08 M USD.
Yes, you can track Antibe Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
ATBPF net income for the last quarter is −3.18 M USD, while the quarter before that showed −3.68 M USD of net income which accounts for 13.74% change. Track more Antibe Therapeutics, Inc. financial stats to get the full picture.
Today Antibe Therapeutics, Inc. has the market capitalization of 7.49 M, it has increased by 57.40% over the last week.
No, ATBPF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ATBPF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Antibe Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 11.00 employees. See our rating of the largest employees — is Antibe Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Antibe Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Antibe Therapeutics, Inc. stock shows the strong sell signal. See more of Antibe Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Antibe Therapeutics, Inc. future price: according to them, ATBPF price has a max estimate of 1.48 USD and a min estimate of 0.11 USD. Read a more detailed Antibe Therapeutics, Inc. forecast: see what analysts think of Antibe Therapeutics, Inc. and suggest that you do with its stocks.